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Abbreviations:  
AJCC: American Joint Committee on Cancer 
CAF: cancer-associated fibroblast 
CMS: consensus molecular subtype 
CRC-SC: colorectal cancer stem cell 
CRC: colorectal cancer 
ctDNA: circulating tumour DNA 
CTL: cytotoxic T lymphocyte 
EMT: epithelial-mesenchymal transition 
EndMT: endothelial-mesenchymal transition 
HSC: hepatic stellate cell 
ISC: intestinal stem cell 
ITH: intratumoral heterogeneity 
MDSC: myeloid-derived suppressor cell 
Met-SC: Metastatic stem cell 
MSC: mesenchymal stem cell 
MSI: microsatellite instable 
SC: stem cell 
TAM: tumour-associated macrophage 
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TAN: tumour-associated neutrophil 
TME: tumour microenvironment 
TNM: tumour, lymph node, metastasis 
UPR: unfolded protein response 
 
Abstract 
Colorectal cancer (CRC) is one of the most common cancer types and 
represents a major therapeutic challenge. Although initial events in colorectal 
carcinogenesis are relatively well-characterized and treatment for early stage 
disease has significantly improved over the last decades, the mechanisms 
underlying metastasis – the main cause of death – remain poorly understood. 
Correspondingly, no effective therapy is currently available for advanced or 
metastatic disease. There is increasing evidence that colorectal cancer is 
hierarchically organized and sustained by cancer stem cells, in concert with various 
stromal cell types. Here we review the interplay between cancer stem cells and their 
microenvironment in promoting metastasis and discuss recent insights relating to 
both patient prognosis and novel targeted treatment strategies. A better 
understanding of these topics may aid the prevention or reduction of metastatic 
burden.  
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1. Introduction 
Colorectal cancer (CRC) is one of the most frequent types of cancer 
worldwide, accounting for approximately 10% of all new cancer cases and 8.5% of 
all cancer deaths (Torre et al., 2015). Whereas the vast majority of primary cancers 
can be extirpated through surgical resection, only a fraction of the patients 
diagnosed with overt metastatic disease can be cured by surgery. About 20% of the 
CRC patients present with metastasis at the time of diagnosis (stage IV). In addition, 
35-45% of the patients with localized disease (stage II and III) succomb to 
recurrence within 5 years after surgery. Most of these relapses occur as metastases 
and are caused by residual tumour cells that have spread to distant organs prior to 
surgery. Clearly, current systemic therapies fail to eliminate latent disseminated 
tumour cells and are similarly ineffective in treating growing metastases, offering 
survival benefits of only a few months.  
Metastasis is the spread of cancer to a distant organ, which in the case of 
CRC patients involves mainly the liver and lungs. As described elsewhere 
(Massague and Obenauf, 2016; Oskarsson et al., 2014; Valastyan and Weinberg, 
2011), to gain metastatic competence, cancer cells require the capacity to invade the 
surrounding tissues, survive in the circulation, colonize the foreign organ and 
eventually resume growth. Metastasis is an inefficient process owing to the fact that 
most tumour cells fail to acquire the necessary abilities to regenerate a tumour at a 
distant site (Massague and Obenauf, 2016; Oskarsson et al., 2014). Over the past 
few years, the main determinants of metastatic competence in CRC have begun to 
be characterized. In the absence of mutations that associate to the process of 
metastasis in CRC, it has become increasingly clear that the regeneration of the 
tumour in a foreign organ is tightly bound to the acquisition of a stem-like phenotype 
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by cancer cells. These metastatic stem cells adopt multiple phenotypes and 
behaviours and critically depend on their interaction with the microenvironment to 
migrate, survive in the circulation and thrive in a foreign organ.  
In section 2 we will review the genetics of CRC development, to then discuss 
both the evidence that supports the notion of hierarchical organization throughout 
CRC progression and the ensuing implications in section 3. We will also focus on the 
mechanisms involved in the multiple phenotypes and adaptations that tumour stem 
cells go through in the metastatic process. In section 4 we will explore the current 
knowledge about the role of the tumour microenvironment in promoting and 
sustaining metastasis. This includes a dissection of the cell types and niches that 
support the survival and maintenance of metastatic stem cells, and an analysis of the 
ways that stromal features can improve disease prognosis. In section 5, we will 
discuss the complexities and limitations imposed on clinical practice by the 
heterogeneous nature of both epithelial and stromal compartments. Finally, we will 
indicate how these emerging concepts are informing, and slowly transforming, 
therapeutic strategies to treat patients with metastatic disease.                  
 
2. Colon carcinogenesis 
2.1. From Normal Mucosa to Colorectal Cancer. 
The epithelium of the normal colon undergoes continuous renewal. At the 
base of glandular invaginations of the colonic mucosa, called crypts, a pool of rapidly 
diving intestinal stem cells (ISCs) sustains the homeostatic regeneration of the 
epithelium throughout a lifetime (Clevers, 2013). Over the past decade, signals that 
regulate ISC renewal and proliferation have been extensively characterized: WNT, 
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EGFR/MAPK and NOTCH signalling promote the undifferentiated proliferative state 
of ISCs in the niche, whereas BMP and TGF-beta signalling induce cytostasis and 
differentiation (Clevers, 2013).       
The elevated division rate of ISCs increases their probability to acquire 
mutations during DNA replication (Vogelstein et al., 2013). Additional environmental 
factors such as life style, diet and microbiota can also greatly influence the 
transformation of the epithelium (Bishehsari et al., 2014). The most common genetic 
events in CRCs are alterations that inactivate the tumour suppressor gene APC. This 
triggers the constitutive activation of WNT signalling and imposes a continuous stem-
like self-renewing state at the onset of tumorigenesis, giving rise to benign 
outgrowths of the epithelium known as adenomas. Genetic experiments performed in 
mouse models support the hypothesis that Apc mutation in ISCs represents the 
origin of intestinal polyps (Barker et al., 2008; Tetteh et al., 2016), although chronic 
inflammation or dysregulation of BMP signalling have been shown to help convert 
non-stem cells into CRC initiating cells (Davis et al., 2014; Schwitalla et al., 2013). 
A small fraction of adenomas become progressively aggressive through 
acquisition of additional driver mutations, which mainly affect 3 additional signalling 
pathways (Cancer Genome Atlas Network, 2012; Seshagiri et al., 2012): i. the MAPK 
pathway is often hit by activating mutations in KRAS, BRAF or PIK3CA and provides 
cell autonomous mitogenic and pro-survival stimuli to cancer cells; ii. the p53 
pathway is inactivated by mutations in the eponymous protein, or less commonly in 
ATM, facilitating acquisition of genomic instability; iii. the TGF-beta pathway is 
frequently silenced by loss-of-function mutations in TGFBR2, SMAD4, SMAD2 or 
SMAD3, which bypasses the suppressive effects of high TGF-beta levels present in 
the tumour microenvironment (Fearon, 2011). Pioneer studies by Eric Fearon and 
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Bert Vogelstein correlated these mutations with pathologically classifiable stages of 
adenoma malignancy and suggested a linear progression model, in which the 
compounding of the 4 mentioned pathway mutations associated with development of 
aggressive adenocarcinomas (Fearon and Vogelstein, 1990).  
Acquisition of these mutations is a slow process and consequently the 
development of invasive CRC often takes decades (Jones et al., 2008; Vogelstein et 
al., 2013). Of note, the linear progression model based on 4 stepwise genetic 
alterations represents a simplification, as not every tumour carries genetic alterations 
in these four pathways or develops through the equivalent sequence of events. 
Moreover, full-blown CRCs have a riche and complex mutational landscape that 
expands well beyond mutations in the 4 driver pathways (Cancer Genome Atlas 
Network, 2012; Seshagiri et al., 2012). Due to the acquisition of chromosomal 
instability or defects in the DNA mismatch repair system, tumours accumulate 
hundreds or even thousands of genetic alterations. Some of these are passenger 
mutations, as they do not confer advantages to tumour cells, but others drive the 
biology of the cancer and therefore give selective advantage. Beyond the context of 
the linear progression model, the role of many of these mutations remains poorly 
understood. Together, these issues of complexity and heterogeneity impinge upon 
the functional analysis of CRC and complicate the development and application of 
therapeutic approaches.  
2.2. Progression to Metastasis 
As described above, the mutations that drive CRC progression affect the 
signalling pathways that regulate ISC behaviour, endowing cancer cells with self-
renewal and growth capacity, independently of crypt niche signals. Evidence 
obtained from the analysis of patient-derived and CRISPR-engineered CRC 
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organoids have led to the hypothesis that acquisition of mutations in the 4 linear 
progression model pathways may be sufficient to facilitate the growth of tumour cells 
in unfavourable environments such as those encountered in foreign tissues (Drost et 
al., 2015; Fujii et al., 2016; Matano et al., 2015). Yet, while most CRCs carry genetic 
alterations in several of these 4 driver pathways, metastasis is a relatively inefficient 
process. This suggests that additional bottlenecks and dependencies limit the extent 
of tumour spread.   
It is worth considering that most CRCs are invasive at the time of diagnosis 
and, therefore, have had the opportunity to shed cells into circulation for months or 
longer. When disseminating CRC cells enter the portal circulation, they are 
transported to the liver sinusoids within minutes and can home into the liver 
parenchyma because of vessel fenestration. In the case of pulmonary metastases, 
CRC cells must first reach the general circulation and then infiltrate the lung 
parenchyma. It has been reported that this process requires active killing of lung 
capillary cells in a mechanism that involves the hormone PTHLH (Urosevic et al., 
2014) and possibly necroptosis (Strilic et al., 2016). The capacity of disseminated 
CRC cells to infiltrate other organs such as the brain is less well-characterized and 
may involve co-option of invasion mechanisms described for other tumour types 
such as breast cancer (Valiente et al., 2014).  
Work in experimental models has shown that the rate-limiting step in the 
metastasis process is the capacity of circulating tumour cells to colonize the foreign 
organ (Massague and Obenauf, 2016; Obenauf and Massagué, 2015). Most tumour 
cells that survive in circulation and manage to infiltrate a distant organ will die for 
reasons that remain incompletely understood but that may include recognition and 
killing of tumour cells by the innate and adaptive immune system (Collignon et al., 
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2004; Strauss and Thomas, 2010). Those tumour cells that survive and adapt to the 
new environment can generate an overt metastasis (Figure 1). However, not all 
venturing cancer cells that have successfully pervaded a distant site necessarily 
have the competency to establish a thriving colony in these hostile environments. 
Frequently, they remain latent for months to years before resuming growth (Sosa et 
al., 2014). Below we discuss tumour cell-intrinsic and extrinsic aspects that facilitate 
metastatic colonization in CRC.  
 
3. Colorectal Cancer Stem Cells and their Role in Metastasis  
Besides (genetic) diversity between patients, no individual CRC is a uniform, 
clonal mass of cancer cells: any given tumour consists of multiple cell populations 
with varying levels of phenotypic and genetic heterogeneity. Intratumoral 
heterogeneity (ITH) is a central concept to understand the phenomena of metastatic 
progression and therapeutic resistance. Three factors contribute to ITH; the 
hierarchical organization of cell lineages (sections 3.1 to 3.3), their clonal 
diversification (section 3.4) and the microenvironment (section 4).       
3.1. Hierarchical Organization of Cancer Cells  
More than 30 years ago it was already proposed that the phenotypic diversity 
in cancers could arise from spontaneous differentiation of tumour cells (Pierce and 
Speers, 1988). The concept, originally developed by G. Barry Pierce in the 70s’, 
states: “[carcinomas] are composed of a mixture of malignant stem cells, which have 
a marked capacity for proliferation and a limited capacity for differentiation under 
normal homeostatic conditions, and of the differentiated, possibly benign, progeny of 
these malignant cells” (Pierce and Speers, 1988). This hypothesis was long ignored, 
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yet several laboratories have recently put forward evidence to support that CRC 
complies with this concept. Of note are studies by the groups of Ruggero de Maria 
(Ricci-Vitiani et al., 2007), John Dick (O’Brien et al., 2007) and Michael Clarke 
(Dalerba et al., 2007), wherein each identified a population of tumour cells within 
human CRCs that has the rare capacity to propagate the disease upon inoculation 
into immunodeficient mice. Re-launching the idea that CRCs are organized through 
a hierarchy of cells with distinct tumorigenic potential, they named this population 
“tumour initiating cells”.  
Subsequent investigation showed that tumour-initiating cells (also referred to 
as CRC Stem Cells or CRC-SCs) reside at the apex of a hierarchy of tumour cells. 
They self-renew, display long-term proliferation potential and are capable of initiating 
tumours when inoculated into mice. CRC-SCs cells express a gene programme that 
to some extent overlaps with that of normal ISCs, and their progeny can undergo 
differentiation towards a phenotype similar to that of the normal mucosa. 
Differentiation coincides with loss of tumorigenic potential (Dalerba et al., 2011; 
Kreso et al., 2014; Merlos-Suarez et al., 2011; Vermeulen et al., 2010, 2008). 
Furthermore, the existence of stem cell hierarchy in CRC has been backed by 
lineage tracing studies in adenomas (Kozar et al., 2013; Schepers et al., 2012) and 
by studies of fate mapping analysis using lentiviral marking of individual tumour cells 
(Dieter et al., 2011; Kreso et al., 2012).  
The balance between stemness and differentiation in CRC depends upon the 
same pathways that regulate normal ISCs, including WNT (Vermeulen et al., 2010), 
BMP (Lombardo et al., 2011) and NOTCH (Lu et al., 2013) signalling. Many of these 
signals are provided by cells of the tumour stroma, a finding that somewhat 
contradicts the hypothesis that CRC progress through gain of ISC niche 
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independency by acquired mutations. Yet, it is worth considering that not every CRC 
carries alterations in all 4 driver pathways (WNT, EGFR, TGF-beta/BMP and p53) 
and thus may still depend on stromal factors for further progression. As is discussed 
below, additional stromal-derived cytokines and growth factors present at the sites of 
invasion can further promote self-renewal of CRC-SCs.  
3.2. Tumour Cell Phenotypes at the Invasion Front 
Because CRC-SCs have both self-renewal and tumour-initiating capacity, 
they likely represent (or give rise to) the so-called Metastatic Stem Cells (Met-SCs, 
Figure 1), i.e. the cell of origin of metastasis (Oskarsson et al., 2014). Experimental 
evidence supports this hypothesis: the abovementioned study by the group of Hanno 
Glimm (Dieter et al., 2011) demonstrates that only cells that hold long-term self-
renewing ability are capable of generating metastasis.  
Most CRCs are a relatively disorganized mixture of stem- and differentiated-
like cells that reside into glandular structures reminiscent of the normal crypts 
(Merlos-Suarez et al., 2011). Metastases often have an equivalent appearance 
(Merlos-Suarez et al., 2011). However, whereas CRC-SCs present in tumour glands 
are tumorigenic if isolated and xenografted into mice, naturally they will only be 
competent to generate metastasis if they first acquire phenotypic changes that 
enable their migration and extravasation. This process is thought to occur when 
cancer cells engage in communication with the adjacent tissues and the tumour 
stroma. A key example is the interaction with endothelial cells, which induce NOTCH 
signalling on cancer cells to facilitate transendothelial migration via the kinase ABL 
and RHO activity at invasion fronts (Sonoshita et al., 2015, 2011) (Figure 2). 
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In the interest of defining Met-SCs, there is a long-standing focus on cancer 
cells at invasion fronts. A frequent finding in CRCs is the presence of tumour buds - 
small clusters of detached cancer cells at the invasive border. These budding cells 
typically possess attributes that help explain their invasive and migratory phenotype, 
including increased expression of genes involved in extracellular matrix degradation 
and in epithelial-mesenchymal transition (EMT) (Zlobec et al., 2010). Moreover, 
cancer cells present at invasion fronts and in tumour buds display increased 
accumulation of nuclear beta-catenin (Brabletz et al., 1998), possibly marking 
stemness. Although most CRCs carry mutations that activate the WNT pathway 
constitutively, a number of signalling molecules emanating from stromal cells such 
as HGF (Vermeulen et al., 2010) and PGE2 (Li et al., 2012) have been shown to 
further elevate WNT signalling in adjacent areas (Figure 2).  In contrast, high levels 
of nuclear beta-catenin at invasion fronts do not always correlate with tumour 
budding and various stem cell markers have been found in only a small fraction of 
budding cells, casting some doubt on their general representation of Met-SCs 
(reviewed in (Dawson and Lugli, 2015)). Notwithstanding these caveats, tumour 
budding has consistently been linked to poor survival and is a prognostic factor 
poised to refine standard clinical risk assessment of early stage CRC (van Wyk et al., 
2015). 
Additional factors derived from the tumour microenvironment that help sustain 
invasiveness and self-renewal of CRC-SCs include IL-22, expressed by a subset of 
T cells (Kryczek et al., 2014), and fibroblast-derived IL-17A (Lotti et al., 2013). 
Perhaps the best example connecting invasion and stemness in CRC is the work by 
Giorgio Stassi, de Maria, and colleagues, who found that a subpopulation of CRC-
SCs expressing the surface marker CD44-v6 is present at invasion fronts and gives 
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rise to metastatic lesions in experimental models (Todaro et al., 2014). CD44-v6 is 
required for cell migration and its expression is increased by factors secreted by 
stromal cells such as HGF, OPN and SDF-1 (Todaro et al., 2014). Together with the 
above-mentioned WNT stimulating mechanisms, these data imply that the 
microenvironment instructs the formation of migratory CRC-SCs, or putative Met-
SCs (Figure 2). 
Following local invasion, CRC cells that enter the vasculature are termed 
circulating tumour cells (CTCs). From a theoretical perspective, both CRC-SCs and 
non-SCs may be able to enter the circulation. Yet, few studies have assessed the 
heterogeneity of CTCs in regard to their stem cell properties, such as CD133 
expression (Iinuma et al., 2011). Still, CTCs have attracted considerable attention for 
their diagnostic potential, although many challenges – including heterogeneity – 
impede their robust detection and thus exploitation (reviewed in (Hardingham et al., 
2015)). In contrast, analysing mutations in circulating tumour DNA (ctDNA) appears 
to be a more straightforward and robust method to detect residual disease and thus 
to assess risk of relapse after therapy in patients with localized disease (Tie et al., 
2016).  
3.3. Slow Proliferating and Dormant Tumour Cells  
As described in the introductory section, metastasis often develops after a 
period of latency, which in CRC typically ranges up to 5 years. Latency is the 
consequence of disseminated cells remaining in a dormant state at distant sites. The 
current therapeutic strategy to eliminate these residual cells is treatment with 
standard chemotherapy, which has a limited benefit for the patients. Indeed, dormant 
and slow proliferating cells are largely resistant to chemotherapy, as this typically 
targets rapidly proliferating cells. In addition, dormant cells remain in a particular 
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state of resilience against cell death-inducing signals and may even be protected 
against attacks of the immune system (Ghajar, 2015; Malladi et al., 2016; Massague 
and Obenauf, 2016). Metastatic latency likely includes two distinct mechanisms: 
population dormancy, a condition in which tumour cell proliferation and death are 
balanced, thus leading to micrometastatic lesions that do not expand; or a state of 
cellular quiescence or temporary mitotic arrest (Ghajar, 2015; Massague and 
Obenauf, 2016).  
The characterization of these mechanisms is of key importance, as a better 
understanding offers opportunities to cure patients by eliminating the residual 
disease (or preventing its outgrowth) before appearance of overt metastasis. 
Although progress in this area has been made for other cancer types (for excellent 
reviews on this topic see (Ghajar, 2015; Massague and Obenauf, 2016)), these 
processes remain poorly elucidated in CRC. Concerning the latter mechanism, fate-
mapping experiments with xenografts support the existence of slow proliferating cells 
even in the tumour bulk. Specifically, not all tumour initiating cells responsible for 
secondary and tertiary transplants had detectably contributed to primary xenografts, 
implying the existence of dormant cells that can reactivate in tumour re-initiation 
(Dieter et al., 2011). Through a similar strategy, such dormant or minor clones were 
found to gain predominance upon chemotherapy treatment (Kreso et al., 2012).  
Whereas the origin, identity and regulation of dormant cell populations in 
CRCs remain unclear, advances in the understanding of cellular diversity of the 
normal intestinal epithelium may provide some clues. In the crypts, most cells 
positive for ISC marker Lgr5 proliferate at high rates and are therefore sensitive to 
treatment with radio- and chemotherapy (Metcalfe et al., 2014; Yan et al., 2012). 
Douglas Winton and colleagues showed that a subset of Lgr5+ cells that are 
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differentiating towards secretory lineages have slow proliferation kinetics and are 
relatively chemoresistant (Buczacki et al., 2013). Although these cells are not 
clonogenic in homeostasis, they regain stemness and contribute to regenerating the 
epithelium after ISC pool depletion by treatment with cytostatic drugs. Likewise, 
lineage tracing experiments in similar settings have shown that differentiated cells of 
the absorptive and secretory lineage can undergo a process of dedifferentiation and 
repopulate the ISC niche, gaining self-renewal capacity (Tetteh et al., 2016, 2015; 
van Es et al., 2012). Thus, differentiated cells constitute a reservoir of facultative 
stem cells in normal mucosa. Given the other parallels with CRC, such as cellular 
hierarchy, it would be clinically relevant to test if these concepts of (population) 
dormancy and plasticity also apply to cancer and metastasis. For example, do latent 
metastatic cells share characteristics – other than chemoresistance – with quiescent 
crypt cells? And does dedifferentiation facilitate CRC recurrence after treatment?  
3.4. Linking Clonal Diversity to Cancer Stem Cell Architecture 
As a result of genomic instability, cancers acquire hundreds of genetic and 
epigenetic alterations that impose distinct phenotypes and fates on tumour cells, 
potentially leading to clonal expansion. This evolutionary phenomenon is the basis 
for the striking capacity of cancer to adapt to different environments, colonize foreign 
organs and resist therapy (Boland and Goel, 2005; Nowell, 1976; Swanton, 2012). In 
CRC, a Big Bang-like model has been proposed in which tumours go through 
extensive clonal diversification at early stages, with little indication for stringent 
selection or clonal expansion. Additionally, malignant behaviour appears to be 
determined early, and can be inferred from analysing subclone intermixing events 
(Sottoriva et al., 2015). From this initial genetic diversity, artificial selection pressure 
in the form of chemotherapy might select for the rise of pre-existing resistant clones 
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(reviewed in (Greaves and Maley, 2012)). For instance, minor populations of KRAS 
mutant cells already present in the primary CRC will expand upon anti-EGFR 
therapy, leading to resistant relapses (Diaz Jr et al., 2012). 
At the conceptual level, the phenotypic heterogeneity resulting from tumour 
cell hierarchy and clonal diversity are not necessarily independent. CRC-SCs likely 
represent the unit of clonal selection, as mutations occurring in more differentiated 
cells may have a lower chance of being selected given the relatively short life-span 
of this population (reviewed in (Greaves and Maley, 2012; Kreso and Dick, 2014; 
Valent et al., 2012). A particularly interesting aspect that has been seldom explored 
is how the genotype affects cellular hierarchy. The WNT (Vermeulen et al., 2010), 
PI3K (Tenbaum et al., 2012), BMP/TGF-beta (Lombardo et al., 2011) signalling 
pathways all affect self-renewal and differentiation capacity of CRC stem cells and 
thus mutations in these pathways likely regulate the frequency of CRC-SCs. It is thus 
possible that successive accumulation of genetic alterations in these pathways 
increases frequencies of CRC-SCs, progressively increasing the probability of 
mutation being selected and thus accelerating evolution, up to a point where full 
compound mutant tumours contain abundant, variegated populations of CRC-SCs 
with limited capacity to produce differentiated progeny. Testing this hypothesis will 
require analysing how the tumour hierarchy changes in distinct mutational 
backgrounds.      
Although clonal diversity has been linked to therapeutic resistance, somatic 
evolution and increased metastatic competency, sequencing of primary CRC and 
metastases has revealed no specific genetic alterations associated to tumour 
dissemination per se (Jones et al., 2008; Mlecnik et al., 2016b). While equivalent 
studies analysing epigenetic marks have not been performed, the similarities 
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between primary tumour and metastasis suggest that non-genetic factors, might be 
of particular relevance in this process. 
 
4. The Microenvironment During Progression to Metastasis 
Heterogeneity between patients and within the CRC epithelial compartment 
already raises significant challenges and opportunities for patient diagnosis and 
treatment. Yet, further augmenting the complexity, ITH also includes the numerous 
additional cell types that permeate the tumour and are collectively referred to as 
stroma or tumour microenvironment (TME). Stromal-associated functions are linked 
to all steps of cancer progression and metastasis, and a picture has emerged in 
which cancer cells and the stroma cross-communicate and co-evolve during cancer 
progression (Hanahan and Coussens, 2012; Quail and Joyce, 2013). Conceptually, 
transformed cancer cells strongly change the nature and composition of the stroma, 
to the point that this altered microenvironment forms an adapted niche, providing 
protection and stimulation, essentially fostering cancer stem cells (Figure 3).  
With the emergence of the TME as a critical player in cancer progression, an 
increasing effort goes into the characterization of specific stromal cell populations 
that are held responsible for tumour malignization and metastatic colonization. 
Several mechanisms have emerged from this endeavour, providing potential targets 
for the design of new anti-cancer therapies. 
4.1. Cancer-Associated Fibroblasts (CAFs) 
CAFs are a heterogeneous group of fibroblasts that are redirected toward 
tumour promotion.  As in other cancers types, CRC-associated fibroblasts differ from 
neighbouring normal fibroblasts and express specific markers including alpha-
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smooth muscle actin (alpha-SMA), fibroblast surface protein (FSP-1) and fibroblast-
activated protein (FAP) (reviewed in (Calon et al., 2014)). CAFs provide CRC cells 
with an array of cytokines that promote cancer cell survival and tumour initiation 
(Kalluri, 2016). Mechanistically, co-inoculated CAFs enhance in vivo tumour growth 
of cancer cells more than normal colon fibroblasts, and soluble factors secreted by 
the former increase self-renewal and migration of epithelial cancer cells to a greater 
extent than those secreted by the latter (Berdiel-Acer et al., 2014). In addition, gene 
expression signatures derived from CAFs correlate with poor outcome in colorectal 
cancer (Becht et al., 2016; Calon et al., 2015; Herrera et al., 2013; Isella et al., 2015). 
Thus, CAFs constitute an important cell population in the TME and provide a 
permissive niche for cancer progression (Figures 2 and 3). 
TGF-beta has been linked to poor prognosis in CRC as an independent 
biomarker across AJCC (American Joint Committee on Cancer) stages and ligand 
expression levels correlate with TGF-beta-activated stromal cells that secrete a 
cocktail of additional pro-metastatic factors (Calon et al., 2012) (Figure 3). Although 
TGF-beta activates a wide range of tumour stroma cell types (Pickup et al., 2013), 
CAFs are the main contributors to the association of stromal TGF-beta-driven 
programmes with poor clinical outcome in CRC, suggesting a predominant role of 
TGF-beta-activated CAFs during progression to metastasis (Calon et al., 2015). 
These activated CAFs express several known pro-metastatic secreted factors 
including angiopoietin-like-4 (ANGPTL-4) (Padua et al., 2008), connective tissue 
growth factor (CTGF) (Kang et al., 2003), tenascin C (TNC) (Oskarsson et al., 2011) 
– functionally described in breast cancer – and Periostin (POSTN), a promoter of 
metastatic growth in colon cancer that increases cell survival via the AKT pathway 
(Bao et al., 2004). In addition to these factors, we found that TGF-beta-activated 
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CAFs secrete interleukin-11 (IL-11), which leads to enhanced STAT-3-dependent 
survival and initiation of metastatic cancer cells (Calon et al., 2012). To support the 
role of this cytokine in CRC progression, an IL-11 antagonist was shown to reduce 
both proliferation and invasive capacity of CRC cells (Putoczki et al., 2013). A recent 
study described an additional function for TGF-beta in promoting liver metastasis by 
the adhesion of cancer cells to CAFs, followed by their subsequent co-dissemination 
to the metastatic site (Gonzalez-Zubeldia et al., 2015).  
Besides the above-mentioned TGF-beta targets, also modifiers of TGF-beta 
signalling may be therapeutically relevant in the context of CAFs and liver metastasis. 
Under physiological condition, hepatic stellate cells (HSCs) are maintained 
unresponsive to TGF-beta through degradation of TGF-beta receptor type-2, by a 
process involving IQGAP1 (IQ motif containing GTPase activating protein). During 
cancer progression, paracrine signalling emanating from cancer cells decreases 
IQGAP1 expression in HSCs, which promotes HSC activation into myofibroblasts as 
well as metastatic outgrowth (Liu et al., 2013). These data indicate that CRC-SCs 
are capable of initiating the formation of a metastatic niche by reprogramming 
resident mesenchymal cells into CAFs (see also below). Furthermore, TGF-beta 
signalling in HSCs was shown to be modulated by platelet-derived growth factor 
receptor (PDGFR)-alpha, leading to paracrine effects on CRC cell proliferation and 
migration (Liu et al., 2014). This adds to the rationale for the inhibition of the PDGFR 
signalling pathway with imatinib, a compound targeting tyrosine kinases including 
PDGFRs. This drug was previously proposed as a therapeutic agent in CRC for its 
effects on impairing migration of bone marrow-derived mesenchymal stem cells 
(MSCs) to the tumour site, resulting in decreased metastatic intake (Shinagawa et al., 
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2013). Incidentally, MSCs have also been reported to differentiated into CAF-like 
cells in the TME (Shinagawa et al., 2010) 
4.2. Endothelial Cells 
The stromal niche surrounding cancer cells comprises a constantly 
developing network of blood vessels, supplying the growing tumour with oxygen and 
nutrients. Secreted factors produced in the tumour stimulate proliferation and 
survival of endothelial cells, thus enhancing angiogenesis. Tumour-associated 
angiogenesis gives rise to abnormal blood vessels characterized by a chaotic 
network, excessive branching, decreased pericyte coverage, and leakiness (Dudley, 
2012). The latter has been associated with metastasis and poor prognosis in patients 
with CRC (Yonenaga et al., 2005). 
VEGFA is a key regulator of endothelial cell proliferation in most human 
tumours, inducing the MAPK/ERK signalling pathway. Tumoral VEGFA expression 
correlates with invasiveness, increased vascular density and progression to 
metastasis. Accordingly, Bevacizumab, a monoclonal antibody against VEGFA and 
an inhibitor of angiogenesis, has been shown to increase survival of Stage IV CRC 
patients when combined with chemotherapy (Ferrara and Adamis, 2016; Hurwitz et 
al., 2004; Mathonnet, 2014) (Figures 2 and 3). Besides blocking neo-angiogenesis, 
the clinical benefit of a dual targeting approach may involve the reprogramming of 
tumour-associated blood vessels into normalized blood vessels by Bevacizumab, 
decreasing vessel permeability, and improving anti-cancer drug bioavailability into 
the tumour mass (Jain, 2005). 
Interleukin-33 (IL-33), a cytokine secreted by endothelial and epithelial cells to 
activate NF-κB and MAPK signalling, may also hold therapeutic interest for the 
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reprogramming of endothelial cells and normalization of tumour vasculature in CRC. 
Tumour-derived IL-33 dramatically enhances neo-angiogenesis by increasing 
endothelial cell proliferation, migration and differentiation into blood vessels to 
robustly increase metastatic spreading of CRC cells to the liver (Zhang et al., 2016). 
Conversely, blockade of IL-33 signalling suppresses angiogenesis and reduces 
tumorigenesis (Maywald et al., 2015).  
Endothelial cells are a part of perivascular niches that have been reported to 
foster cancer stem cells (Butler et al., 2010). A mechanism in which endothelial cells 
directly promote the formation of CRC-SCs, involves a soluble form of Jagged-1 to 
activate NOTCH signalling in cancer cells (Lu et al., 2013) (Figure 2). Another way in 
which endothelial cells might participate more directly in niche formation is their 
conversion into CAF-like cells, through a TGF-beta-driven mechanism called 
endothelial-mesenchymal transition (EndMT). This process is associated with the up-
regulation of fibroblast-specific protein-1 (FSP-1) and down-regulation of the 
endothelial marker CD31 (Zeisberg et al., 2007). Although the existence of EndMT in 
CRC remains elusive, a similar mechanism was reported in response to 
inflammation in the colon (Rieder et al., 2011). 
4.3. Immune Cells  
As the immune system can be a powerful weapon against tumorigenesis 
through coordinated elimination of aberrant cells, successful cancers find a way to 
circumvent tumour immunity; this is recognized as a hallmark of cancer (Hanahan 
and Weinberg, 2011). In fact, it has become increasingly clear that the immune 
system has a dual role in cancer, both able to suppress and promote cancer 
progression (Schreiber et al., 2011).  Even if a thriving cancer suggests inhibition of 
the former and exploitation of the latter, there is evidence for a continued battle 
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between the immune system and cancer cells. First, there is a positive prognostic 
value of the presence of infiltrating immune cells such as T cells (Galon et al., 2006) 
and dendritic cells (Gulubova et al., 2012), as well as high levels of gene signatures 
of active immune responses (Galon et al., 2006). Conversely, the presence in blood 
and tumour of immunosuppressive myeloid-derived suppressor cells (MDSCs) 
(Solito et al., 2011; Sun et al., 2012) correlates with a poor prognosis. Second, 
cancers show signs of immunoselection, where the number of neoantigens is lower 
than expected based on mutation rates. This can be caused by T cell-mediated 
killing of cells or clones expressing immunogenic neoantigens (Matsushita et al., 
2012) or by loss of antigen expression or presentation (DuPage et al., 2012; Rooney 
et al., 2015).   
Together, this indicates that evasion from anti-tumour immunity is only partial, 
local, or reversible, and that immunity is likely a key hurdle to overcome in the 
metastatic process. Relatedly, metastatic latency and population dormancy have 
been linked to immunosurveillance in a melanoma model, where (micro-) metastasis 
growth was equilibrated by immunologic cancer cell killing (Eyles et al., 2010), 
(reviewed in (Giancotti, 2013; Sosa et al., 2014)). Although many of these important 
concepts are emerging for cancer in general (Vinay et al., 2015), less is known about 
the specific situation in CRC. Nevertheless, below are some recently described 
mechanisms that together have an important impact on the prospects of 
immunotherapies. 
4.3.1. Innate Immune Cells 
Besides their role in innate immunity and the coordination of adaptive immune 
responses, several bone marrow-derived myeloid cells have been linked to tumour 
progression (Taketo, 2009). Chemokine signalling may play an important role in their 
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recruitment and subsequent communication with CRC cells and other TME residents, 
often promoting both cancer progression and metastasis (Itatani et al., 2016) (Figure 
3). Immature myeloid cells positive for C-C chemokine receptor type 1 (CCR1) have 
been linked to CRC progression and liver metastasis (Kitamura et al., 2010, 2007), in 
a mechanism that involves the loss of SMAD4 in CRC cells, triggering CCL15-
mediated recruitment of CCR1+ myeloid cells (Hirai et al., 2014; Itatani et al., 2013). 
Similar mechanisms link MDSCs to CRC progression through the action of CCL15 
(Inamoto et al., 2016) or CCL2 (Chun et al., 2015).  
Macrophages, one of the most abundant tumour infiltrating cell types, have 
been ascribed many tumour suppressor roles in CRC, ranging from direct 
cytotoxicity to orchestrating and sustaining adaptive responses (Braster et al., 2015). 
Besides this classical functional state (often called M1), alternative activation states 
like M2 (also referred to as tumour-associated macrophages or TAMs) have been 
described; these are characterized by mostly pro-tumorigenic potential (reviewed in 
(Mantovani et al., 2009)). Polarization of macrophages is incompletely understood 
but appears to be plastic and largely dependent on the TME (reviewed in (Braster et 
al., 2015)). Recently, a lot of attention has gone towards the clinical implication of the 
presence, plasticity and dual functions of TAMs (Braster et al., 2015; Mantovani and 
Allavena, 2015). For example, their accumulation at the liver metastatic periphery 
was recently shown to lend itself for exploitation, when a gene transfer strategy 
delivered interferon alpha to the TME via Tie2+ monocytes/macrophages in a mouse 
model for CRC metastasis, resulting in reduced tumour growth and enhanced 
survival (Catarinella et al., 2016) (Figure 3).   
Like macrophages, neutrophils (a class of granulocytes), have been found to 
undergo functional repolarization in the TME, a process that involves TGF-beta 
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(Fridlender et al., 2009) and converts them into a pro-tumorigenic state (N2 vs N1). 
Tumour-associated neutrophils (TANs), like MDSCs, can be recruited to SMAD4-
mutant metastatic cancer cells by CCL15 and help promote lung colonization 
(Yamamoto et al., 2016). In addition, a recent report links neutrophils to cancer 
recurrence after surgery through a defence mechanism involving the release of 
neutrophil chromatin strands: neutrophil extracellular traps (Tohme et al., 2016). 
These may be possible explanations for the emergence of a high neutrophil to 
lymphocyte ratio as a potential poor prognosis marker for CRC patients (Li et al., 
2014).  
4.3.2. Adaptive Immune Cells 
Specialized, adaptive immune responses heavily rely on cells from the 
lymphoid lineage, including T cells and B cells. Central mediators of adaptive 
responses are CD8+ cytotoxic T lymphocytes (CTLs) that recognize specific antigens. 
For their function, they require assistance and reinforcement from CD4+ T helper 
cells as well as from myeloid cells. CTL infiltration in CRC is a factor for good 
prognosis and lack thereof indicates poor disease outcome (Galon et al., 2006; Naito 
et al., 1998; Ropponen et al., 1997), indicating that T cell-mediated immune 
surveillance plays an important role in CRC metastasis. Therefore, microsatellite 
instable (MSI) cancers, bearing multiple mutations that can translate into aberrant 
(peptide) antigens, may be linked to good prognosis – in large measure -- because 
of effective adaptive immune responses (Kloor and von Knebel Doeberitz, 2016; 
Rooney et al., 2015).  
A growing number of recent therapeutic strategies aim to enhance existing T 
cell responses, and early results point to successes mainly in MSI cancers (see 
section 5.4). Besides reprogramming neutrophils, TGF-beta has been shown to 
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repolarize various other immune cell types, including natural killer cells, dendritic 
cells, macrophages and T cells (Flavell et al., 2010), and to directly inhibit T cell 
mechanisms (Chen et al., 2005; Thomas and Massague, 2005; Yang et al., 2010; 
Zhang et al., 2005). Moreover, dendritic cells, MDSCs and tumour-associate 
macrophages are all, like CAFs, sources for stromal TGF-beta (Gabrilovich and 
Nagaraj, 2009), indicating a  mechanism in which TGF-beta reprograms a variety of 
stromal cells, amplifying its own signal, and impeding anti-cancer immune responses 
in a concerted way. 
4.4. Heterogeneity of the TME as a Tool to Stratify CRC Patients 
As described above, an understanding of the extent of intra- and inter-tumour 
variegation helps frame the limited accuracy of the generic AJCC staging system in 
predicting disease outcome, and has provided a number of additional parameters for 
prognostic use. Numerous findings underscore the prognostic value of immune cells 
in the tumour stroma during cancer progression. As mentioned above, the work by 
Jérôme Galon and colleagues showed that an index evaluating the type and 
localization of immune cells (Immunoscore) can predict disease outcome. Indeed, 
they demonstrated a stronger prognostic power than the classical TNM (Tumour, 
lymph Node, Metastasis) system (Galon et al., 2014, 2006, Mlecnik et al., 2016a, 
2016b).  
Furthermore, since the development of DNA microarray technology, there has 
been a growing interest in refining CRC patient stratification with unbiased molecular 
classification based on gene expression profiles (Blanco-Calvo et al., 2015; Golub et 
al., 1999). A series of recent studies have identified between three and six molecular 
subtypes of CRCs associated with distinct outcome and response to treatment 
(Budinska et al., 2013; De Sousa E Melo et al., 2013; Marisa et al., 2013; Roepman 
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et al., 2014; Sadanandam et al., 2013; Schlicker et al., 2012). To consolidate the 
various classifiers, a consortium of experts in the field of molecular classification 
integrated these molecular stratifications of CRC into four consensus molecular 
subtypes (CMS) (Guinney et al., 2015). CMS1 includes most of the MSI and CpG 
Island Methylation Phenotype (CIMP)-high CRCs whereas CMS2, CMS3 and CMS4 
are chromosomal instable tumours displaying roughly equivalent genotypes yet 
distinct expression profiles. CRCs belonging to CMS2 express a gene programme 
that suggest elevated WNT/MYC activation and thus they may represent the 
canonical class of CRC. CMS3 cancers express signatures that reflect particular 
metabolic reprogramming, and those of CMS4 display elevated expression of 
mesenchymal genes.  
Importantly, CMS4 is associated with poor outcome. Whereas mesenchymal 
gene expression was initially attributed to cancer cells undergoing EMT, two studies 
revealed that the signatures that identified patients with the worst outcome were in 
fact of stromal origin (Calon et al., 2015; Isella et al., 2015). Recent analysis also 
suggest that the gene expression profile of the CMS4 subtype reflects 
immunosuppression (Becht et al., 2016). Importantly, the power of stromal gene 
signatures to predict disease relapse outperforms both the classical AJCC staging 
system and the consensus molecular stratification of patients (Calon et al., 2015; 
Isella et al., 2015). As mentioned in earlier sections, further investigation within these 
prognostic stromal gene signatures identified a prominence of TGF-beta target 
genes expressed by CAFs in the most aggressive tumours, which are promising 
poor-prognosis biomarkers that can be assessed using either transcriptomic or 
immunohistochemical techniques (Calon et al., 2015, 2012). Altogether, these data 
suggest that stromal evaluation will greatly benefit upcoming patient classification 
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systems and may translate to better clinical assessment of the disease as well as 
provide new avenues for therapeutic intervention. 
 
5. Specific Targeting of Cell Types to Treat Metastasis  
For many years, the standard of care for advanced disease had been 5-
fluoruouracil – commonly supplemented with folinic acid – which only confered a 
marginal survival advantage. Somewhat more encouraging results emerged from the 
addition of oxaliplatin or irinotecan to the regimen (FOLFOX or FOLFIRI, 
respectively) both in metastatic disease (de Gramont et al., 2000; Douillard et al., 
2000) and as adjuvant therapy in some stage II and most stage III CRC  patients 
(André et al., 2009; Van Cutsem et al., 2016). However, these systemic 
chemotherapies in effect indiscriminately kill proliferative cells and their therapeutic 
index is limited for many patients. Moreover, this approach neither targets dormant 
CRC-SCs, nor offers an answer to resistance or stromal mitigation. Understanding 
intratumoral heterogeneity and the biology of the different cell types that populate the 
tumour is guiding the development of new therapeutic strategies to treat advanced 
disease. 
5.1. Targeted therapies 
Standard systemic chemotherapy is increasingly combined with targeted 
treatments that eliminate specific dysregulated pathways crucial for cancer growth or 
survival. For example, inhibitors of EGFR signalling such as Cetuximab and 
Panitumumab improve survival in CRC patients (Van Cutsem et al., 2016) (Figure 3). 
Unfortunately, these therapies are met with both intrinsic and acquired resistance in 
the vast majority of cases, often involving mutations downstream to EGFR (including 
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in KRAS and BRAF genes), but also in other mitogenic protein kinase receptor 
signalling pathways (Bertotti et al., 2015).  
As additional targeted therapies become available, the development of 
increasingly adding cancer genome and transcriptome sequencing to regular clinical 
practice might help in this systematic approach of targeting signalling networks most 
relevant to individual tumours. However, clonal diversity can severely complicate this 
class of analysis (see section 3.4). Additionally, signalling networks perturbed in one 
way can rewire elsewhere and confer resistance, indicating a challenge in providing 
straight-forward biomarkers for response for targeted therapies (Prahallad et al., 
2012). Therapies combining multiple pathway inhibitors are being tested as way to 
prevent resistance to individual drugs but these strategies may face important toxic 
effects on normal tissues that limit their implementation. 
5.2. Anti-Cancer Stem Cell Therapies.  
The hierarchical organization of CRC has led to the hypothesis that the cause 
of disease relapse is that standard chemotherapy eliminates the tumour bulk while 
sparing CRC-SCs. While formal proof for this idea is still lacking, several initiatives to 
develop anti-CRC-SC therapies are currently ongoing. There are three classes of 
such therapies. First, targeting the key pathways that regulate the behaviour of CRC-
SCs – including WNT, NOTCH, EGFR and TGF-beta/BMP – is an obvious approach 
to prevent the maintenance or expansion of this cell population. Whereas inhibitors 
and agonist of these pathways exist, they are not always effective, given the fact that 
CRCs carry genetic alterations that alter many or all of these pathways. For instance, 
CRC-SCs depend on WNT signalling to sustain self-renewal and inhibitors of WNT 
secretion and of WNT receptors are in advanced stages of testing. Yet, the vast 
majority of CRCs carry mutations in the tumour suppressor gene APC, which 
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constitutively activate the pathway downstream of the receptor. Unfortunately, 
developing inhibitors that target pathway components downstream of APC has 
proven to be tremendously challenging (Anastas and Moon, 2012; Kahn, 2014), until 
two recent studies reported promising compounds. The first, called NCB-0846, 
inhibits TNIK (an essential regulatory component of WNT/beta-catenin signalling 
(Mahmoudi et al., 2009)) and effectively abrogates CRC stemness in vitro and polyp 
formation in mice (Masuda et al., 2016). The second (called MSAB) binds to beta-
catenin and promotes its proteasomal degradation, inhibiting the growth of xenograft 
tumours in mice (Hwang et al., 2016) (Figure 2).  A drawback of this class of 
strategies is the fact that normal ISCs also critically depend on the same pathways 
as CRC-SCs, which may lead to strong side effects.  
A second therapeutic strategy is to deplete CRC-SCs through the use of 
antibodies-drug conjugates (ADCs) designed to bind surface antigens express by 
this cell population. As recently shown, antibodies targeting Lgr5 coupled to different 
toxins demonstrated potent anti-tumour efficacy in preclinical models of CRC 
(Junttila et al., 2015) (Figure 3). Again, this strategy may also have significant side 
effects given the fact that many surface makers of CRC-SCs are shared with normal 
ISCs. Furthermore, as discussed in section 3.3, if stress-induced dedifferentiation in 
the normal crypt has its parallel in cancer, regeneration of CRC-SCs pool by 
conversion of non-SCs cells upon cessation of the treatment may also limit the 
effectiveness of this strategy (Figure 3). 
A third strategy relies on identifying molecules and dependencies specific for 
CRC-SCs that can be targeted therapeutically, supposedly without major toxicities. 
For instance, targeting self-renewal of CRC-SCs using an inhibitor of BMI1 (PTC-
209) has been shown to have robust therapeutic effects (Kreso et al., 2014). ER-
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stress-induced activation of the unfolded protein response (UPR) forces CRC-SCs to 
differentiate and therefore drugs that induce UPR could have therapeutic activity 
against this cell population (Wielenga et al., 2015). Furthermore, a low-dose of the 
DNA-demethylating agent 5-AZA-CdR induces viral-like response in CRC-SCs by 
triggering the expression of double stranded RNAs derived from endogenous 
retroviral elements, which has an anti-tumoral effect (Roulois et al., 2015) (Figure 3). 
5.3. Stromal Therapies 
In line with the growing realization that a large number of stromal cells are 
actively involved in driving CRC progression (including maintenance of CRC-SCs), 
new strategies are taking shape wherein either the TME is the main target, or a 
combination of agents attack both cancer cells and stromal cells, to improve 
therapeutic response and prevent acquired resistance (Fang and Declerck, 2013). 
For example, a recent study suggested that HGF secreted by fibroblasts might 
decrease the response to irinotecan. The successful reversion of such resistance 
using anti-HGF targeted therapy (Woo et al., 2015) emphasizes the promises of 
multi-targeted treatments for patients (Figure 3). This strategy might also be of high 
value for CRC patients with non-mutated KRAS gene where resistance to inhibitors 
of EGFR is associated to increased levels of HGF (Liska et al., 2011; Takahashi et 
al., 2014). 
As mentioned in section 4.2, another group of widely applied agents for CRC 
treatment in fact target the TME. These drugs inhibit VEGF signalling in endothelial 
cells and thereby oppose tumour vascularization. Besides monoclonal antibodies, 
also a recombinant fusion protein (aflibercept, blocking VEGFA, VEGFB and 
placental growth factor signalling) was shown to improve survival in phase III trials 
on selected metastatic CRC patients (Van Cutsem et al., 2012). However, the 
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majority of responsive patients tend to develop resistance to anti-angiogenic 
therapies over time, in part because the hypoxic conditions established during 
treatment may independently cause further malignization of cancer cells (Ulivi et al., 
2016). Nevertheless, anti-angiogenic therapies are likely to continue to be part of 
future combinatory treatment strategies. 
Instead of targeting elements in the TME for depletion or destruction, an 
attractive alternative is the repolarization of stromal cells into a non-permissive state, 
for instance by blocking or reverting the corruptive signals from cancer cells. In this 
perspective, stromal reprogramming might have a lower toxicity than destructive 
therapies and can thus be a powerful tool to combine with more conventional 
treatments. The many stromal pro-tumorigenic functions associated to TGF-beta in 
CRC (and other cancers) suggest that its successful and safe inhibition would be an 
invaluable therapeutic goal. In a mouse model of metastatic initiation, stromal TGF-
beta signalling enhanced metastatic spreading while therapeutic inhibition of this 
pathway in the stroma with galunisertib abrogated liver metastasis initiation by CRC 
cells (Calon et al., 2015, 2012) (Figure 3). Extensive discussion on the 
implementation of anti-TGF-beta therapies for advanced CRC can be found 
elsewhere (Tauriello and Batlle, 2016). 
5.4. Immunotherapies 
It has been proposed that conventional chemotherapy may in a large part rely 
on immune components to be efficient, for instance by causing immunologic cell 
death (Zitvogel et al., 2013). Consequently, T cells infiltration of both the primary 
tumour and liver metastases has been associated with response to chemotherapy in 
patients with metastatic CRC (Halama et al., 2011, 2009). Immunotherapies – which 
aim to directly induce of immune responses, or to enhance pre-existing ones – have 
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seen impressive efficacies in a growing number of cancer types (Palucka and 
Coussens, 2016). Designed to activate tumour-specific CD8+ CTL immune 
responses, cancer vaccines have demonstrated benefit in prostate cancer, 
melanoma and other cancer types (Butterfield, 2015) and several strategies have 
been developed for CRC (Xiang et al., 2013). Many such treatments focussed on 
advanced (metastatic) disease have had disappointing responses, possibly in part 
because of the progressively immunosuppressive TMEs of those tumours, 
suggesting a higher benefit at earlier stages (Merika et al., 2010). Recently, 
promising results were reported for a vaccine based on a Mucin 1 peptide in 
prophylactic treatment of patients with precancerous adenomas (Kimura et al., 2013). 
Even in this study, treatment failure was linked to the presence of high levels of 
immunosuppressive MDSCs already at early this early stage, which might be a 
useful biomarker for further exploration of similar strategies as well as indicate these 
cells can be therapeutic target themselves. To circumvent both the requirement of in 
situ activation and the problem of tumoral immune tolerance, a passive form of 
immunotherapy can be used, where in vitro activated immune effectors (most often T 
cells) are administered to the patient. However, early trials with adoptive cell therapy 
resulted in severe toxicities and were not efficacious (Xiang et al., 2013). 
Early clinical trials with a different type of immunotherapy, checkpoint 
inhibition – which unblocks T cell-mediated adaptive anti-cancer responses, have 
shown benefit in at least a subset of CRC patients (Puzzoni et al., 2016; Zumwalt 
and Goel, 2015) (Figure 3). Notably responsive are hyper-mutated MSI tumours, 
which commonly carry many neoantigens, are heavily infiltrated by T lymphocytes, 
and express relatively higher levels of various checkpoints (Diaz  Jr. and Le, 2015; 
Kloor et al., 2010; Llosa et al., 2015). However, even in microsatellite-stable CRCs, 
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there is a correlation between mutational/neoantigen load, immune infiltration and 
survival (Giannakis et al., 2016), offering a perspective on successful future 
exploitation of immunotherapies. Several clinical trials are ongoing, evaluating the 
benefit of checkpoint inhibitors like anti-CTLA-4 or anti-PD-1 antibodies (Moehler et 
al., 2016). In addition, combinations of multiple checkpoint inhibitors, or of such 
agents with other strategies such as vaccines and/or chemotherapy, are likely to 
increase the number of patients with good responses (Sharma and Allison, 2015). 
Alternatively, immunotherapy can be designed to inhibit pro-tumorigenic 
interactions between immune cells and neoplastic CRC cells. In a phase I trial, 
cancer-stromal crosstalk through accumulating myeloid cells and T cells, and pro-
tumorigenic cytokine signalling was successfully targeted using anti-CCR5 therapy in 
patients with advanced/metastatic CRC (Halama et al., 2016) (Figure 3). As TGF-
beta is a classical immune suppressor as well as a key modulator of cellular 
crosstalk, the discovery that high levels of TGF-beta correlate with poor prognosis 
may imply that colorectal cancer exploit this cytokine in tumoral immune evasion, 
besides affecting CAF-mediated secretion of protumorigenic factors (Tauriello and 
Batlle, 2016). It will be of great interest to study the effects of this therapeutic 
strategy in immunocompetent models, as well as explore the putative role of CAFs 
as immunosuppressors (Feig et al., 2013; Kraman et al., 2010). Indeed, TGF-beta 
inhibition, for which several approaches are in clinical trials (Akhurst and Hata, 2012; 
Neuzillet et al., 2015; Smith et al., 2012), might acts as or synergize with 
immunotherapy. 
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6. Concluding remarks 
Taken together, recent data discussed here emphasize the importance of 
tumour heterogeneity – in terms of cellular hierarchy, clonal diversity and tumour 
microenvironment – in modulating CRC progression and metastasis (Figure 1). 
These factors have strong implications for patient stratification as well as for the 
development, optimization, and application of therapeutic strategies (Figures 2 and 
3). While key mechanisms and dependencies in cancer progression and metastasis 
are increasingly being translated into targeted therapies, it is vital to integrate these 
emerging concepts both in the selection of patients for clinical testing of new agents, 
and in combining approved therapies for the treatment of individual patients.  
All types of heterogeneity play a role in generating and maintaining colorectal 
cancer stem cells (CRC-SCs) with chemoresistance and metastatic competency, 
and especially the TME supports metastatic colonization (Figures 2 and 3). 
Therefore, therapies that target any or several of the mechanisms discussed here 
may potentially be able to prevent metastasis from developing in the 40-50% of 
patients with early stage disease at risk for distant recurrence. Moreover, several of 
these therapies may be very beneficial for advanced/metastatic CRC patients. 
Among these promising therapeutic strategies are treatments that target CRC-SCs 
directly or through their dependency on the TME. In addition, a deeper 
understanding of colorectal cancer immunity may lead to a better exploitation of 
immunotherapeutic options, as well as offer opportunities in targeting 
immunosuppressive mechanisms.  
The fast pace of progress as well as the high number of open questions in 
each of the research fields we have borrowed from assure that there will be 
significant challenges ahead in our understanding of the full complexity of CRC as a 
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heterogeneous disease. Breaking our inability to effectively treat metastasis requires 
the concerted effort of a large number of researchers and clinicians, and will likely 
involve patient-specific combination of therapies aimed at targeted elimination of 
metastatic competency mechanisms.  
 
Figure legends 
Figure 1. Types of heterogeneity underlying the process of CRC metastasis. 
Schematic representation of a primary tumour with clonal diversity (represented by 
different colours), tumour microenvironment (different cell shapes) and cellular 
hierarchy: colorectal cancer stem cells (CRC-SCs) are drawn with darker colours 
than non-stem cells (non-SCs). In addition, metastatic stem cells (Met-SCs) are 
represented by thicker outlines. There are distinct steps (blue arrows) along the 
metastatic process, each with attrition rates: survival in the vasculature during 
migration, overcoming mechanisms of latency and managing to establish an overt 
metastatic colony. During these events, interactions with the microenvironment that 
promote survival, immune evasion, dormancy/proliferation, and stemness are 
thought to determine outcome. Below: legends depict a basic scheme of cellular 
hierarchy and the wealth of stromal cell types. 
 
Figure 2. Mechanisms and therapeutic opportunities in early dissemination. In 
the centre is a cancer stem cell (CRC-SC) that is in the process of invasion (which 
might involve EMT or tumour budding) or vascular migration. Depicted are various 
recently described interactions with stromal cells: proteins expressed by stromal cells 
are depicted in black, processes in bold, activated pathways in red and relevant 
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cellular markers are written in blue (drawn inside grey labels). Agents or inhibitors 
that target pathways or proteins are drawn in green. See the main text for more 
details. 
 
Figure 3. Mechanisms and therapeutic opportunities in the metastatic setting. 
In the centre is a metastatic stem cell (Met-SC) that is in the process of colonizing 
the liver. Depicted are various recently described interactions with stromal cells: 
proteins expressed by stromal cells are depicted in black, processes in bold, 
activated pathways in red and relevant cellular markers are written in blue (drawn 
inside grey labels). Agents, inhibitors or therapeutic strategies that target pathways 
or proteins are drawn in green. See the main text for more details. 
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